Gunma University Initiative for Advanced Research > Laboratory > Integrated Oncology Research > Dr. KAWABATA Laboratory

Dr. KAWABATA Laboratory

Genome/Omics Oncology Research

  • Explore new therapeutic cancer targets through a data-driven approach!
  • Next generation sequencer analysis requests

Research Fields

Genomic medicine, oncology


Omics analysis, next-generation sequencing, bioinformatics, data science

Difficulties in diagnosing and treating cancer

In recent years, various gene mutations that can cause cancer have been identified with comprehensive cancer genome and transcriptome analyses that use next-generation sequencers. Molecular-targeted drugs that target these mutations have been developed, and with cancer gene panel tests therapies can be conducted that match the respective genetic mutation, and as a result cancer treatment has made remarkable progress. However, cancer is a highly variable disease, and only a small percentage of patients have mutations in which such therapies can be conducted. The percentage of cases in which cancer gene panel tests actually lead to a treatment that matches the genetic abnormality is around 10%, and this low accessibility is a major challenge. In 40% of all cases, the target gene abnormality is not identified. In addition, even if treatment is performed, there are also cases that become drug resistant, and as a result treatment is not effective anymore. Our aim is to create new cancer treatment strategies by integrating and analyzing not only gene mutations but also comprehensive information on RNA, proteins, and metabolites by effectively utilizing accumulated omics data using machine learning and other bioinformatics methods for identifying new therapeutic targets and targets for overcoming drug resistance.

In collaboration with the Laboratory for Analytical Instruments, Education and Research Support Center, Gunma University Graduate School of Medicine, we also perform analysis requests for next-generation sequencers from inside and outside of Gunma University. For more information about analysis requests please contact us under the following e-mail address↓
ngs-service (a) [the @ symbol has been replaced with “(a)”].

Research Policy of the Kawabata Laboratory


  • Bilguun EO*, Kaira K*, Kawabata-Iwakawa R*, Rokudai S, Shimizu K, Yokobori T, Oyama T, Shirabe K, Nishiyama M.
    Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine. BMC Cancer, 20(1):935 , 2020.
    *co-first authors
  • George J, Saito M, Tsuta K, Iwakawa R, Shiraishi K, Scheel A, Uchida S, Watanabe SI, Nishikawa R, Noguchi M, Peifer M, Petersen I, Jang SJ, Buttners R, Harris CC, Yokota J, Thomas RK, Kohno T.
    Genomic amplification of CD274 (PD-L1) in small cell lung cancer.
    Clin Cancer Res, 23(5):1220-1226, 2017.
  • Iwakawa R, Kohno T, Totoki Y, Shibata T, Tsuchihara K, Mimaki S, Tsuta K, Narita Y, Nishikawa R, Noguchi M, Harris C, Robles A, Yamaguchi R, Imoto S, Miyano S, Totsuka H, Yoshida T, Yokota J.
    Expression and Clinical Significance of Genes Frequently Mutated in Small Cell Lung Cancers Defined by Whole Exome/RNA Sequencing.
    Carcinogenesis, 36(6):616-21 , 2015.